Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 1/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | RHEB | Q15382 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089239 | 0.89 | PLA2G4A (0.51) | PLA2G4AGRM2HDAC3HDAC1HDAC2 | |
| SCHEMBL1250934 | 0.89 | GP6 (0.51) | PLA2G4AGRM2PLGPLAUIDO1 | |
| SCHEMBL1248028 | 0.89 | ATM (0.51) | PLA2G4AKDM4CGRM2PLGPLAU | |
| SCHEMBL4088566 | 0.89 | GRM2 (0.49) | PLA2G4AKDM4CGRM2HDAC3HDAC1 | |
| SCHEMBL12914817 | 0.89 | PLA2G4A (0.48) | PLA2G4AKDM4CGRM2PLGPLAU | |
| SCHEMBL1250386 | 0.89 | GRM2 (0.48) | PLA2G4AGRM2PLGPLAUIDO1 | |
| SCHEMBL4102508 | 0.89 | IDO1 (0.53) | RPA1PLA2G4AKDM4CGRM2CXCR3 | |
| SCHEMBL4105676 | 0.89 | TP53 (0.54) | PLA2G4AGRM2PLGPLAUAGTR1 | |
| SCHEMBL12892289 | 0.88 | PLA2G4A (0.50) | PLA2G4AGRM2HDAC3HDAC1HDAC2 | |
| SCHEMBL4103980 | 0.87 | GRM2 (0.48) | PLA2G4AKDM4CGRM2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | RPA1 1658/4885PLA2G4A 4850/4885KDM4C 4761/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | RPA1 1133/4885PLA2G4A 4116/4885KDM4C 4833/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | RPA1 984/4885PLA2G4A 4510/4885KDM4C 4700/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | RPA1 808/4885PLA2G4A 4747/4885KDM4C 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.